Gut Repair & Microbiome Restoration
BPC-157 and KPV identity for GI-adjacent research. Mouse and gastric-cytoprotection papers are not a leaky-gut, IBS, Crohn’s, or UC protocol.
Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.
Compounds on this goal
BPC-157
recoveryAccelerates the healing of the intestinal endothelium by promoting angiogenesis (new blood vessel formation) and heavily modulating the nitric oxide system in the digestive tract.
Open peptide leaf →KPV
recoveryAlpha-MSH-derived tripeptide that inhibits NF-kB signaling - the master regulator of inflammatory responses. Transported into intestinal cells via PepT1 (which is upregulated during gut inflammation, creating preferential accumulation at sites of damage).
Open peptide leaf →Oral bioregulator option
For an oral bioregulator option, Vita-Stream's US-made Vita Peptides line has Stomek (stomach peptides; helps maintain normal gastric mucosa balance) and the Vita Detox digestive complex.
Affiliate link: Kymata Health earns a commission at no extra cost to you. Supplement statements have not been evaluated by the FDA; not intended to diagnose, treat, cure, or prevent any disease. · Full review
Evidence note on this goal
Protocol evidence level (from existing goal data): Preclinical
- Neither BPC-157 nor KPV is FDA-approved for any indication
- Virtually all evidence comes from animal models and cell culture; human clinical trials are severely lacking
- Oral bioavailability of BPC-157 depends heavily on formulation (Arginine salt vs. acetate)
- KPV dosing in humans is entirely extrapolated from preclinical data - no established human therapeutic doses